Efficacy and tolerability of riluzole in psychiatric disorders: A systematic review and preliminary meta-analysis
- PMID:31254879
- DOI: 10.1016/j.psychres.2019.06.020
Efficacy and tolerability of riluzole in psychiatric disorders: A systematic review and preliminary meta-analysis
Abstract
There is a pressing need for better pharmacological treatment strategies for psychiatric disorders as current treatment often results in partial symptom remission and unwanted side effects. A point of entry may be the glutamatergic system since glutamatergic dysregulation contributes to multiple psychiatric disorders. We evaluated the evidence from randomized controlled trials (RCTs) regarding the use of the glutamatergic drug riluzole in mental illnesses; and conducted preliminary meta-analyses of its effectiveness in treating obsessive-compulsive disorder (OCD) and depression. A systematic search was performed using PubMed (Medline), Embase, Cochrane Database of Systematic Reviews and PsycINFO. Meta-analyses were performed using Comprehensive Meta-Analysis software. Twenty-three RCTs were included for qualitative analysis and showed positive effects of adjunctive/monotherapy riluzole in patients with OCD, depression, autism, substance abuse and schizophrenia. Seven studies were also used for quantitative analysis, which revealed positive but non-significant effects on OCD and depression. Riluzole was generally well tolerated with few serious adverse events. The studies included in this systematic review were highly heterogeneous and the number of studies was limited per diagnostic condition. Moreover, few studies have examined riluzole as a single treatment. We suggest carrying out further work to provide definitive evidence for the benefit of riluzole in psychiatric illness.
Keywords: Meta-analysis; Psychiatric disorder; Riluzole; Systematic review.
Copyright © 2019 Elsevier B.V. All rights reserved.
Similar articles
- Effects of riluzole on psychiatric disorders with anxiety or fear as primary symptoms: A systematic review.Kawashima Y, Yamada M, Furuie H, Kuniishi H, Akagi K, Kawashima T, Noda T, Yamada M.Kawashima Y, et al.Neuropsychopharmacol Rep. 2023 Sep;43(3):320-327. doi: 10.1002/npr2.12364. Epub 2023 Jul 18.Neuropsychopharmacol Rep. 2023.PMID:37463744Free PMC article.Review.
- Efficacy and safety of riluzole for depressive disorder: A systematic review and meta-analysis of randomized placebo-controlled trials.Yao R, Wang H, Yuan M, Wang G, Wu C.Yao R, et al.Psychiatry Res. 2020 Feb;284:112750. doi: 10.1016/j.psychres.2020.112750. Epub 2020 Jan 7.Psychiatry Res. 2020.PMID:31958711
- Should we expand the toolbox of psychiatric treatment methods to include Repetitive Transcranial Magnetic Stimulation (rTMS)? A meta-analysis of the efficacy of rTMS in psychiatric disorders.Slotema CW, Blom JD, Hoek HW, Sommer IE.Slotema CW, et al.J Clin Psychiatry. 2010 Jul;71(7):873-84. doi: 10.4088/JCP.08m04872gre. Epub 2010 Mar 9.J Clin Psychiatry. 2010.PMID:20361902
- Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial.Coric V, Taskiran S, Pittenger C, Wasylink S, Mathalon DH, Valentine G, Saksa J, Wu YT, Gueorguieva R, Sanacora G, Malison RT, Krystal JH.Coric V, et al.Biol Psychiatry. 2005 Sep 1;58(5):424-8. doi: 10.1016/j.biopsych.2005.04.043.Biol Psychiatry. 2005.PMID:15993857Clinical Trial.
- Review of the use of the glutamate antagonist riluzole in psychiatric disorders and a description of recent use in childhood obsessive-compulsive disorder.Grant P, Song JY, Swedo SE.Grant P, et al.J Child Adolesc Psychopharmacol. 2010 Aug;20(4):309-15. doi: 10.1089/cap.2010.0009.J Child Adolesc Psychopharmacol. 2010.PMID:20807069Free PMC article.Review.
Cited by
- Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression.Vecera CM, C Courtes A, Jones G, Soares JC, Machado-Vieira R.Vecera CM, et al.Pharmaceuticals (Basel). 2023 Nov 7;16(11):1572. doi: 10.3390/ph16111572.Pharmaceuticals (Basel). 2023.PMID:38004437Free PMC article.Review.
- The Associations between Mental Well-Being and Adherence to Physical Activity Guidelines in Patients with Cardiovascular Disease: Results from the Scottish Health Survey.Salman A, Sellami M, Al-Mohannadi AS, Chun S.Salman A, et al.Int J Environ Res Public Health. 2019 Sep 26;16(19):3596. doi: 10.3390/ijerph16193596.Int J Environ Res Public Health. 2019.PMID:31561424Free PMC article.
- Effects of riluzole on psychiatric disorders with anxiety or fear as primary symptoms: A systematic review.Kawashima Y, Yamada M, Furuie H, Kuniishi H, Akagi K, Kawashima T, Noda T, Yamada M.Kawashima Y, et al.Neuropsychopharmacol Rep. 2023 Sep;43(3):320-327. doi: 10.1002/npr2.12364. Epub 2023 Jul 18.Neuropsychopharmacol Rep. 2023.PMID:37463744Free PMC article.Review.
- Administration of the glutamate-modulating drug, riluzole, after stress prevents its delayed effects on the amygdala in male rats.Datta S, Rashid Z, Naskar S, Chattarji S.Datta S, et al.PNAS Nexus. 2023 May 22;2(6):pgad166. doi: 10.1093/pnasnexus/pgad166. eCollection 2023 Jun.PNAS Nexus. 2023.PMID:37266396Free PMC article.
- Hippocampal Hyperactivity as a Druggable Circuit-Level Origin of Aberrant Salience in Schizophrenia.Kätzel D, Wolff AR, Bygrave AM, Bannerman DM.Kätzel D, et al.Front Pharmacol. 2020 Oct 16;11:486811. doi: 10.3389/fphar.2020.486811. eCollection 2020.Front Pharmacol. 2020.PMID:33178010Free PMC article.Review.
Publication types
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Full Text Sources
Medical